A Safety Study of Mebendazole in Children 2 to 10 Years of Age

Phase 3 Completed 397 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.

Timeline

Start: 2010-02
Primary completion: 2010-03
Completion: 2010-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mebendazole	Small molecule	500 mg	Oral

Indications

No indication recorded.